Effect of Grape seed extract in treatment of fatty liver

The effect of grape seed extract supplementation on glycemic status, lipid profile, plasma atherogenic index, liver enzymes, anthropometric indices and some inflammatory and antioxidant indices in overweight and obese patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190731044392N1

Enrollment

Registered

2022-03-30

Start date

2022-04-21

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Daily intake of 260 mg grape seed extract supplement (twice a day and two tablets equivalent to 2.5 g each time) for 60 days. Intervention 2: Control group: Recipie

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 20-60 years old patient with non alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Patients who have diabetes, cardiovascular, kidney and other hepatic diseases Pregnant or lactating women Smoking Alcohol consumption Use of dietary supplements

Design outcomes

Primary

Measure	Time frame
Aspartate aminotransferase. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Alanine aminotransferase. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Interlukine-6. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Total antioxidant capacity. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Total cholestrol. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;LDL-C. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;HDL-C. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Triglyciride. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Atherogenic index of plasma. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Formula.;Fasting blood sugar. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Hemoglobin A1c. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Insulin. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Weight. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Digital scale.;Body mass index. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Waist circumference. Timepoint: Before intervention and 2 months after intervention. Method of measurement: By measuring tape according to meter.;Hip circumference. Timepoint: Before intervention and 2 months after intervention. Method of measurement: By measuring tape according to meter.	—

Measure

Time frame

Aspartate aminotransferase. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Alanine aminotransferase. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Interlukine-6. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Total antioxidant capacity. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Total cholestrol. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;LDL-C. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;HDL-C. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Triglyciride. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Atherogenic index of plasma. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Formula.;Fasting blood sugar. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Hemoglobin A1c. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Insulin. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Blood test.;Weight. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Digital scale.;Body mass index. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Body weight in kilograms divided by height squared in meters.;Waist circumference. Timepoint: Before intervention and 2 months after intervention. Method of measurement: By measuring tape according to meter.;Hip circumference. Timepoint: Before intervention and 2 months after intervention. Method of measurement: By measuring tape according to meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Razmi

Ahvaz University of Medical Sciences

hamidrezarazmi95@gmail.com+98 61 3333 3050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026